The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over
- PMID: 15149776
- DOI: 10.1016/j.vaccine.2003.11.052
The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over
Abstract
The number needed to treat (NNT) and population extensions of the NNT describe the population outcomes of disease treatment, usually for chronic diseases. We have developed similar measures for vaccine preventable diseases based on the number needed to vaccinate. These measures quantify the number of people, or the number of vaccine doses, needed to prevent one event due to disease per year and allow the calculation of the vaccine cost to prevent one event due to disease per year. We used this method to compare influenza and pneumococcal vaccine programmes for people aged 65 years or more. We calculated the vaccine cost (dollars AUD) to prevent a case of disease, a hospitalisation or a death due to influenza or invasive pneumococcal disease each year in this age group. For influenza, the vaccine costs were dollars 598 to prevent one case per year, dollars 10787 per hospitalisation prevented and dollars 74801 per death prevented each year. We assumed all cases of invasive pneumococcal disease were hospitalised so the vaccine cost of dollars 11494 per case prevented was the same as the vaccine cost per hospitalisation prevented, while the vaccine cost per death prevented each year was dollars 49972. These results suggest the vaccine costs for the prevention of one hospitalisation or one death each year due to invasive pneumococcal disease among the elderly in Australia would be similar to the costs for the prevention of one hospitalisation or death due to influenza.
Similar articles
-
Cost-effectiveness analysis of influenza and pneumococcal vaccinations among elderly people in Japan.Kobe J Med Sci. 2006;52(3-4):97-109. Kobe J Med Sci. 2006. PMID: 16855372
-
Could a federal program to promote influenza vaccination among elders be cost-effective?Prev Med. 2006 Mar;42(3):240-6. doi: 10.1016/j.ypmed.2005.12.004. Epub 2006 Feb 15. Prev Med. 2006. PMID: 16480761
-
[Pharmaco-economic aspects of vaccination against invasive pneumococcal infections in persons over 65 years of age; review of the literature on cost effectiveness analysis].Ned Tijdschr Geneeskd. 2002 May 4;146(18):855-9. Ned Tijdschr Geneeskd. 2002. PMID: 12038224 Dutch.
-
Vaccine-preventable influenza disease burden from clinical trials of Vaxigrip - an inactivated split virion influenza vaccine - supports wider vaccine use.Vaccine. 2007 Nov 7;25(45):7720-31. doi: 10.1016/j.vaccine.2007.08.063. Epub 2007 Sep 20. Vaccine. 2007. PMID: 17920168 Review.
-
Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older.Am J Prev Med. 2006 Jul;31(1):72-9. doi: 10.1016/j.amepre.2006.03.008. Am J Prev Med. 2006. PMID: 16777545 Review.
Cited by
-
Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021-February 2022, VISION Network: a retrospective cohort study.Lancet Reg Health Am. 2023 Jul;23:100530. doi: 10.1016/j.lana.2023.100530. Epub 2023 Jun 14. Lancet Reg Health Am. 2023. PMID: 37333688 Free PMC article.
-
The burden of COVID-19 in French Guiana: Vaccine-averted deaths, hospitalizations and costs.Vaccine X. 2023 Apr;13:100271. doi: 10.1016/j.jvacx.2023.100271. Epub 2023 Feb 11. Vaccine X. 2023. PMID: 36819215 Free PMC article.
-
A Comparative Analysis of Influenza-Associated Disease Burden with Different Influenza Vaccination Strategies for the Elderly Population in South Korea.Vaccines (Basel). 2022 Aug 25;10(9):1387. doi: 10.3390/vaccines10091387. Vaccines (Basel). 2022. PMID: 36146465 Free PMC article.
-
Number Needed to Quarantine and Proportion of Prevented Infectious Days by Quarantine: Evaluating the Effectiveness of COVID-19 Contact Tracing.Public Health Rep. 2022 Nov-Dec;137(6):1178-1186. doi: 10.1177/00333549221114343. Epub 2022 Aug 20. Public Health Rep. 2022. PMID: 35989593 Free PMC article.
-
Recurrent invasive meningococcal infections - quantifying the risk, Germany, 2002 to 2018.Euro Surveill. 2020 Jun;25(25):1900565. doi: 10.2807/1560-7917.ES.2020.25.25.1900565. Euro Surveill. 2020. PMID: 32613936 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
